---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-041137"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:56:28.191562+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Anebulo Q1 FY2024 net loss $2.5M; FDA positive on Phase 3 path for ANEB-001

## Summary
- Net loss of $2.5M ($0.10/sh) vs $2.6M ($0.11/sh) in prior year quarter; operating expenses $2.5M.
- Cash $8.5M as of Sep 30; secured credit facility of up to $10M from existing investors.
- FDA Type B meeting: single ED study plus larger THC challenge may suffice for NDA for ANEB-001.
- Richie Cunningham appointed CEO and Board member; Bimal Shah joined Board; Phase 3 targeted H1 2024.

## SEC filing metadata
- accession: 0001493152-23-041137
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315223041137/0001493152-23-041137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315223041137/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-041137
- JSON: https://secwatch.observer/filing/0001493152-23-041137.json
- Plain text: https://secwatch.observer/filing/0001493152-23-041137.txt

## Key facts
- Earnings Releases
  Anebulo Pharmaceuticals, Inc. reported three months ended September 30, 2023 results: net income $2.5 million, or $(0.10) per share, EPS $(0.10) per share.
  - Period: three months ended September 30, 2023
  - Net income: $2.5 million, or $(0.10) per share
  - EPS: $(0.10) per share
  - Result: reported results
  source text: Net loss in the first quarter of fiscal 2024 was $2.5 million, or $(0.10) per share, compared with a net loss of $2.6 million, or $(0.11) per share, in the first quarter of fiscal 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315223041137/0001493152-23-041137-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.